Hagop Kantarjian

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Philadelphia Chromosome

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Vega-Ruiz Arturo; Cortes Jorge E; Sever Matjaz; Manshouri Taghi; Quintás-Cardama Alfonso; Luthra Raja; Kantarjian Hagop M; Verstovsek Srdan
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Thomas Deborah A; O'Brien Susan; Kantarjian Hagop M
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Thomas Deborah A; Ravandi Farhad; Keating Michael; Kantarjian Hagop M
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Hagop Kantarjian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Vega-Ruiz Arturo; Cortes Jorge E; Sever Matjaz; Manshouri Taghi; Quintás-Cardama Alfonso; Luthra Raja; Kantarjian Hagop M; Verstovsek Srdan
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Leukemia research 2009;33(11):1481-4.
2009: Thomas Deborah A; O'Brien Susan; Kantarjian Hagop M
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Hematology/oncology clinics of North America 2009;23(5):949-71, v.
2009: Thomas Deborah A; Ravandi Farhad; Keating Michael; Kantarjian Hagop M
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.
Leukemia & lymphoma 2009;50 Suppl 1():27-31.
2009: Cortes Jorge E; Kantarjian Hagop M; Goldberg Stuart L; Powell Bayard L; Giles Francis J; Wetzler Meir; Akard Luke; Burke John M; Kerr Robert; Saleh Mansoor; Salvado August; McDougall Karen; Albitar Maher; Radich Jerald;
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4754-9.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop M; Manshouri Taghi; Thomas Deborah; Cortes Jorge; Ravandi Farhad; Garcia-Manero Guillermo; Ferrajoli Alessandra; Bueso-Ramos Carlos; Verstovsek Srdan
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Konoplev Sergej; Huang Xuelin; Drabkin Harry A; Koeppen Hartmut; Jones Dan; Kantarjian Hagop M; Garcia-Manero Guillermo; Chen Weina; Medeiros L Jeffrey; Bueso-Ramos Carlos E
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
Cancer 2009;115(20):4737-44.
2009: Mak Duncan H; Schober Wendy D; Chen Wenjing; Konopleva Marina; Cortes Jorge; Kantarjian Hagop M; Andreeff Michael; Carter Bing Z
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Molecular cancer therapeutics 2009;8(9):2509-16.
2009: Tefferi Ayalew; Verstovsek Srdan; Barosi Giovanni; Passamonti Francesco; Roboz Gail J; Gisslinger Heinz; Paquette Ronald L; Cervantes Francisco; Rivera Candido E; Deeg H Joachim; Thiele Juergen; Kvasnicka Hans M; Vardiman James W; Zhang Yanming; Bekele B Nebiyou; Mesa Ruben A; Gale Robert P; Kantarjian Hagop M
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4563-9.
2009: Jabbour Elias; Jones Daniel; Kantarjian Hagop M; O'Brien Susan; Tam Constantine; Koller Charles; Burger Jan A; Borthakur Gautam; Wierda William G; Cortes Jorge
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114(10):2037-43.
2009: Verma Dushyant; Kantarjian Hagop M; Jones Dan; Luthra Rajyalakshmi; Borthakur Gautam; Verstovsek Srdan; Rios Mary Beth; Cortes Jorge
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood 2009;114(11):2232-5.
2009: Zhang Wenyong W; Cortes Jorge E; Yao Hui; Zhang Li; Reddy Neelima G; Jabbour Elias; Kantarjian Hagop M; Jones Dan
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3642-9.
2009: Kantarjian Hagop M; Shan Jianqin; Jones Daniel; O'Brien Susan; Rios Mary Beth; Jabbour Elias; Cortes Jorge
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3659-63.
2009: Abdel-Wahab Omar; Mullally Ann; Hedvat Cyrus; Garcia-Manero Guillermo; Patel Jay; Wadleigh Martha; Malinge Sebastien; Yao JinJuan; Kilpivaara Outi; Bhat Rukhmi; Huberman Kety; Thomas Sabrena; Dolgalev Igor; Heguy Adriana; Paietta Elisabeth; Le Beau Michelle M; Beran Miloslav; Tallman Martin S; Ebert Benjamin L; Kantarjian Hagop M; Stone Richard M; Gilliland D Gary; Crispino John D; Levine Ross L
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood 2009;114(1):144-7.
2009: Quintás-Cardama Alfonso; Cortes Jorge E; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Liu David; Bleickardt Eric; Chen Tai-Tsang; Kantarjian Hagop M
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: Issa Jean-Pierre J; Kantarjian Hagop M
Targeting DNA methylation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):3938-46.
2009: Thomas Deborah A; O'Brien Susan; Jorgensen Jeffrey L; Cortes Jorge; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Koller Charles; Pierce Sherry; Huh Yang; Wierda William; Keating Michael J; Kantarjian Hagop M
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Blood 2009;113(25):6330-7.
2009: Faderl Stefan; Pal Ashutosh; Bornmann William; Albitar Maher; Maxwell David; Van Quin; Peng Zhenghong; Harris David; Liu Zhiming; Hazan-Halevy Inbal; Kantarjian Hagop M; Estrov Zeev
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Cancer research 2009;69(9):3910-7.
2009: Jabbour Elias; Garcia-Manero Guillermo; Taher Ali; Kantarjian Hagop M
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
The oncologist 2009;14(5):489-96.
2009: Fava Carmen; Kantarjian Hagop M; Jabbour Elias; O'Brien Susan; Jain Nitin; Rios Mary Beth; Garcia-Manero Guillermo; Ravandi Farhad; Verstovsek Srdan; Borthakur Gautam; Shan Jianqin; Cortes Jorge
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Kantarjian Hagop M
Introduction: targeting different pathways to prevent tumor cell development.
Seminars in oncology 2009;36(2 Suppl 1):S1-5.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop M; Cortes Jorge E
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Cancer control : journal of the Moffitt Cancer Center 2009;16(2):122-31.
2009: Ye Dongjiu; Garcia-Manero Guillermo; Kantarjian Hagop M; Xiao Lianchun; Vadhan-Raj Saroj; Fernandez Michael H; Nguyen Martin H; Medeiros L Jeffrey; Bueso-Ramos Carlos E
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
Journal of hematopathology 2009;2(1):2-8.
2009: Jabbour Elias; Kantarjian Hagop M; Jones Dan; Shan Jenny; O'Brien Susan; Reddy Neeli; Wierda William G; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Cortes Jorge
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Blood 2009;113(10):2154-60.
2009: Kantarjian Hagop M; O'Brien Susan
Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens.
Blood 2009;113(8):1861; author reply 1862.
2009: Jabbour Elias; Cortes Jorge E; Kantarjian Hagop M
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Mayo Clinic proceedings. Mayo Clinic 2009;84(2):161-9.
2009: Kantarjian Hagop M; Larson Richard A; Guilhot Francois; O'Brien Stephen G; Mone Manisha; Rudoltz Marc; Krahnke Tillmann; Cortes Jorge; Druker Brian J;
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Cancer 2009;115(3):551-60.
2009: Tsimberidou Apostolia-Maria; Wen Sijin; McLaughlin Peter; O'Brien Susan; Wierda William G; Lerner Susan; Strom Sara; Freireich Emil J; Medeiros L Jeffrey; Kantarjian Hagop M; Keating Michael J
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):904-10.
2009: Yang Hui; Kadia Tapan; Xiao Lianchun; Bueso-Ramos Carlos E; Hoshino Koyu; Thomas Deborah Ann; O'Brien Susan; Jabbour Elias; Pierce Sherry; Rosner Gary L; Kantarjian Hagop M; Garcia-Manero Guillermo
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
Blood 2009;113(9):1892-8.
2009: Tsimberidou Apostolia-Maria; Tam Constantine; Abruzzo Lynne V; O'Brien Susan; Wierda William G; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):373-80.
2009: Kornblau Steven M; Tibes Raoul; Qiu Yi Hua; Chen Wenjing; Kantarjian Hagop M; Andreeff Michael; Coombes Kevin R; Mills Gordon B
Functional proteomic profiling of AML predicts response and survival.
Blood 2009;113(1):154-64.
2009: Sekeres Mikkael A; Elson Paul; Kalaycio Matt E; Advani Anjali S; Copelan Edward A; Faderl Stefan; Kantarjian Hagop M; Estey Elihu
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Blood 2009;113(1):28-36.
2009: Apostolidou Effrosyni; Kantarjian Hagop M; Verstovsek Srdan
JAK2 inhibitors: A reality? A hope?
Clinical lymphoma & myeloma 2009;9 Suppl 3():S340-5.
2008: O'Brien Susan; Thomas Deborah; Ravandi Farhad; Faderl Stefan; Cortes Jorge; Borthakur Gautum; Pierce Sherry; Garcia-Manero Guillermo; Kantarjian Hagop M
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Jabbour Elias; Kantarjian Hagop M; Jones Dan; Reddy Neeli; O'Brien Susan; Garcia-Manero Guillermo; Burger Jan; Cortes Jorge
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Blood 2008;112(13):4839-42.
2008: Faderl Stefan; Ferrajoli Alessandra; Wierda William; Huang Xuelin; Verstovsek Srdan; Ravandi Farhad; Estrov Zeev; Borthakur Gautam; Kwari Monica; Kantarjian Hagop M
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; Keating Michael J; O'Brien Susan; Brandt Mark; Pierce Sherry; Freireich Emil J; Medeiros L Jeffrey; Estey Elihu
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Cancer 2008;113(6):1370-8.
2008: Jones Dan; Thomas Deborah; Yin C Cameron; O'Brien Susan; Cortes Jorge E; Jabbour Elias; Breeden Megan; Giles Francis J; Zhao Weiqiang; Kantarjian Hagop M
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Tam Constantine S; Nussenzveig Roberto M; Popat Uday; Bueso-Ramos Carlos E; Thomas Deborah A; Cortes Jorge A; Champlin Richard E; Ciurea Stefan E; Manshouri Taghi; Pierce Sherry M; Kantarjian Hagop M; Verstovsek Srdan
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Blood 2008;112(5):1628-37.
2008: Faderl Stefan; Ravandi Farhad; Huang Xuelin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Borthakur Gautam; Verstovsek Srdan; Thomas Deborah A; Kwari Monica; Kantarjian Hagop M
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Kroeger Heike; Jelinek Jaroslav; Estécio Marcos R H; He Rong; Kondo Kimie; Chung Woonbok; Zhang Li; Shen Lanlan; Kantarjian Hagop M; Bueso-Ramos Carlos E; Issa Jean-Pierre J
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.
Blood 2008;112(4):1366-73.
2008: Shah Neil P; Kantarjian Hagop M; Kim Dong-Wook; Réa Delphine; Dorlhiac-Llacer Pedro E; Milone Jorge H; Vela-Ojeda Jorge; Silver Richard T; Khoury H Jean; Charbonnier Aude; Khoroshko Nina; Paquette Ronald L; Deininger Michael; Collins Robert H; Otero Irma; Hughes Timothy; Bleickardt Eric; Strauss Lewis; Francis Stephen; Hochhaus Andreas
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3204-12.
2008: Manshouri Taghi; Quintás-Cardama Alfonso; Nussenzveig Roberto H; Gaikwad Amos; Estrov Zeev; Prchal Josef; Cortes Jorge E; Kantarjian Hagop M; Verstovsek Srdan
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Cancer science 2008;99(6):1265-73.
2008: Jabbour Elias; Cortes Jorge E; Kantarjian Hagop M
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Cancer 2008;112(10):2112-8.
2008: Yu Zhifeng; Sun Baohua; Kantarjian Hagop M; Keating Michael J; Amin Hesham M; Sun Xiaoping
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.
Leukemia & lymphoma 2008;49(4):751-6.
2008: Faderl Stefan; Gandhi Varsha; Kantarjian Hagop M
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Current opinion in hematology 2008;15(2):101-7.
2008: Jabbour Elias; Kantarjian Hagop M; Koller Charles; Taher Ali
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Cancer 2008;112(5):1089-95.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; O'Brien Susan; Cortes Jorge; Wierda William G; Koller Charles; Pierce Sherry; Brandt Mark; Freireich Emil J; Keating Michael J; Estey Elihu H
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Oki Yasuhiro; Jelinek Jaroslav; Shen Lanlan; Kantarjian Hagop M; Issa Jean-Pierre J
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Blood 2008;111(4):2382-4.
2008: Garcia-Manero Guillermo; Yang Hui; Bueso-Ramos Carlos; Ferrajoli Alessandra; Cortes Jorge; Wierda William G; Faderl Stefan; Koller Charles; Morris Gail; Rosner Gary; Loboda Andrey; Fantin Valeria R; Randolph Sophia S; Hardwick James S; Reilly John F; Chen Cong; Ricker Justin L; Secrist J Paul; Richon Victoria M; Frankel Stanley R; Kantarjian Hagop M
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood 2008;111(3):1060-6.
2008: Hochhaus Andreas; Druker Brian; Sawyers Charles; Guilhot Francois; Schiffer Charles A; Cortes Jorge; Niederwieser Dietger W; Gambacorti-Passerini Carlo; Stone Richard M; Goldman John; Fischer Thomas; O'Brien Stephen G; Reiffers Jose J; Mone Manisha; Krahnke Tillmann; Talpaz Moshe; Kantarjian Hagop M
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Blood 2008;111(3):1039-43.
2008: Kurzrock Razelle; Kantarjian Hagop M; Blascovich Michelle A; Bucher Cindy; Verstovsek Srdan; Wright John J; Pilat Susan R; Cortes Jorge E; Estey Elihu H; Giles Francis J; Beran Miloslav; Sebti Said M
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Tsimberidou Apostolia M; Wierda William G; Plunkett William; Kurzrock Razelle; O'Brien Susan; Wen Sijin; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Garcia-Manero Guillermo; Estrov Zeev; Kipps Thomas J; Brown Jennifer R; Fiorentino Albert; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2008: Jabbour Elias; Cortes Jorge E; Ghanem Hady; O'Brien Susan; Kantarjian Hagop M
Targeted therapy in chronic myeloid leukemia.
Expert review of anticancer therapy 2008;8(1):99-110.
2007: Kantarjian Hagop M
Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas.
Seminars in oncology 2007;34(6 Suppl 5):S1-2.
2007: Ferrajoli Alessandra; Faderl Stefan; Van Quin; Koch Patricia; Harris David; Liu Zhiming; Hazan-Halevy Inbal; Wang Yongtao; Kantarjian Hagop M; Priebe Waldemar; Estrov Zeev
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Cancer research 2007;67(23):11291-9.
2007: Ravandi Farhad; Burnett Alan K; Agura Edward D; Kantarjian Hagop M
Progress in the treatment of acute myeloid leukemia.
Cancer 2007;110(9):1900-10.
2007: Kantarjian Hagop M; Giles Francis; Gattermann Norbert; Bhalla Kapil; Alimena Giuliana; Palandri Francesca; Ossenkoppele Gert J; Nicolini Franck-Emmanuel; O'Brien Stephen G; Litzow Mark; Bhatia Ravi; Cervantes Francisco; Haque Ariful; Shou Yaping; Resta Debra J; Weitzman Aaron; Hochhaus Andreas; le Coutre Philipp
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Tsimberidou Apostolia M; Wen Sijin; O'Brien Susan; McLaughlin Peter; Wierda William G; Ferrajoli Alessandra; Faderl Stefan; Manning John; Lerner Susan; Mai Chinh V; Rodriguez Alma M; Hess Mark; Do Kim-Anh; Freireich Emil J; Kantarjian Hagop M; Medeiros L Jeffrey; Keating Michael J
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Kantarjian Hagop M; Jeha Sima; Gandhi Varsha; Wess Michael; Faderl Stefan
Clofarabine: past, present, and future.
Leukemia & lymphoma 2007;48(10):1922-30.
2007: Jabbour Elias; Kantarjian Hagop M; Abruzzo Lynne V; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Soriano Andres O; Yang Hui; Faderl Stefan; Estrov Zeev; Giles Francis; Ravandi Farhad; Cortes Jorge; Wierda William G; Ouzounian Souzanne; Quezada Andres; Pierce Sherry; Estey Elihu H; Issa Jean-Pierre J; Kantarjian Hagop M; Garcia-Manero Guillermo
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Torres Harrys A; Aguilera Elizabeth A; Mattiuzzi Gloria N; Cabanillas Maria E; Rohatgi Nidhi; Sepulveda Carmen A; Kantarjian Hagop M; Jiang Ying; Safdar Amar; Raad Issam I; Chemaly Roy F
Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia.
Haematologica 2007;92(9):1216-23.
2007: Plimack Elizabeth R; Kantarjian Hagop M; Issa Jean-Pierre
Decitabine and its role in the treatment of hematopoietic malignancies.
Leukemia & lymphoma 2007;48(8):1472-81.
2007: Sun Xiaoping; Zhang Wei; Ramdas Latha; Stivers David N; Jones Daniel M; Kantarjian Hagop M; Estey Elihu H; Vadhan-Raj Saroj; Medeiros L Jeffrey; Bueso-Ramos Carlos E
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(8):811-20.
2007: Jabbour Elias; Cortes Jorge E; Giles Francis J; O'Brien Susan; Kantarjian Hagop M
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: Aribi Ahmed; Kantarjian Hagop M; Estey Elihu H; Koller Charles A; Thomas Deborah A; Kornblau Steven M; Faderl Stefan H; Laddie Nakia M; Garcia-Manero Guillermo; Cortes Jorge E
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Kantarjian Hagop M; Cortes Jorge; Guilhot Francçois; Hochhaus Andreas; Baccarani Michele; Lokey Lee
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer 2007;109(7):1365-75.
2007: Borthakur Gautam; O'Brien Susan; Wierda William G; Thomas Deborah A; Cortes Jorge E; Giles Francis J; Kantarjian Hagop M; Lerner Susan; Keating Michael J
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Kantarjian Hagop M; O'Brien Susan; Huang Xuelin; Garcia-Manero Guillermo; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Davisson Jan; Bueso-Ramos Carlos E; Issa Jean-Pierre
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: Kantarjian Hagop M
Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions.
Cancer 2007;109(6):1007-10.
2007: Oki Yasuhiro; Kantarjian Hagop M; Gharibyan Vazganush; Jones Dan; O'brien Susan; Verstovsek Srdan; Cortes Jorge; Morris Gail M; Garcia-Manero Guillermo; Issa Jean-Pierre J
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Cancer 2007;109(5):899-906.
2007: Hochhaus Andreas; Kantarjian Hagop M; Baccarani Michele; Lipton Jeffrey H; Apperley Jane F; Druker Brian J; Facon Thierry; Goldberg Stuart L; Cervantes Francisco; Niederwieser Dietger; Silver Richard T; Stone Richard M; Hughes Timothy P; Muller Martin C; Ezzeddine Rana; Countouriotis Athena M; Shah Neil P
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
2007: Kantarjian Hagop M
Recent experience with decitabine in MDS.
Clinical advances in hematology & oncology : H&O 2007;5(2):140.
2007: Kantarjian Hagop M; Giles Francis; Quintás-Cardama Alfonso; Cortes Jorge
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Roboz Gail J; Giles Francis J; Ritchie Ellen K; Allen-Bard Sandra; Curcio Tania J; Wilkes Meredith A; Park S Lani; Kantarjian Hagop M; Faderl Stefan; Ravandi Farhad; Kelner Michael J; Feldman Eric J
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Han Xin; Garcia-Manero Guillermo; McDonnell Timothy J; Lozano Guillermina; Medeiros L Jeffrey; Xiao Lianchun; Rosner Gary; Nguyen Martin; Fernandez Michael; Valentin-Vega Yasmine A; Barboza Juan; Jones Daniel M; Rassidakis Georgios Z; Kantarjian Hagop M; Bueso-Ramos Carlos E
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(1):54-62.
2007: Kantarjian Hagop M; O'Brien Susan; Shan Jianqin; Aribi Ahmed; Garcia-Manero Guillermo; Jabbour Elias; Ravandi Farhad; Cortes Jorge; Davisson Jan; Issa Jean-Pierre
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2007: Pan Jingxuan; Quintás-Cardama Alfonso; Kantarjian Hagop M; Akin Cem; Manshouri Taghi; Lamb Peter; Cortes Jorge E; Tefferi Ayalew; Giles Francis J; Verstovsek Srdan
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2007: Faderl Stefan; Ferrajoli Alessandra; Harris David; Van Quin; Kantarjian Hagop M; Estrov Zeev
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.
Leukemia research 2007;31(1):91-5.
2006: Kantarjian Hagop M; Talpaz Moshe; Giles Francis; O'Brien Susan; Cortes Jorge
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Zhao Weiqiang; Claxton David F; Medeiros L Jeffrey; Lu Di; Vadhan-Raj Saroj; Kantarjian Hagop M; Nguyen Martin H; Bueso-Ramos Carlos E
Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
The American journal of surgical pathology 2006;30(11):1436-44.
2006: Garcia-Manero Guillermo; Kantarjian Hagop M; Sanchez-Gonzalez Blanca; Yang Hui; Rosner Gary; Verstovsek Srdan; Rytting Michael; Wierda William G; Ravandi Farhad; Koller Charles; Xiao Lianchun; Faderl Stefan; Estrov Zeev; Cortes Jorge; O'brien Susan; Estey Elihu; Bueso-Ramos Carlos; Fiorentino Jackie; Jabbour Elias; Issa Jean-Pierre
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Alvarez Ricardo H; Kantarjian Hagop M; Cortes Jorge E
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Cancer 2006;107(8):1918-29.
2006: Appelbaum Frederick R; Kopecky Kenneth J; Tallman Martin S; Slovak Marilyn L; Gundacker Holly M; Kim Haesook T; Dewald Gordon W; Kantarjian Hagop M; Pierce Sherry R; Estey Elihu H
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
British journal of haematology 2006;135(2):165-73.
2006: Alvarez Ricardo H; Kantarjian Hagop M; Cortes Jorge E
Biology of platelet-derived growth factor and its involvement in disease.
Mayo Clinic proceedings. Mayo Clinic 2006;81(9):1241-57.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Kantarjian Hagop M; Koller Charles; Hagemeister Fredrick B; Fayad Luis; Lerner Susan; Bueso-Ramos Carlos E; Keating Michael J
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Onciu Mihaela; Schlette Ellen; Zhou Yinmei; Raimondi Susana C; Giles Francis J; Kantarjian Hagop M; Medeiros L Jeffrey; Ribeiro Raul C; Pui Ching-Hon; Sandlund John T
Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
Cancer 2006;107(5):1084-92.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Oki Yasuhiro; Jelinek Jaroslav; Beran Miloslav; Verstovsek Srdan; Kantarjian Hagop M; Issa Jean-Pierre J
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
Haematologica 2006;91(8):1147-8.
2006: Tefferi Ayalew; Cortes Jorge; Verstovsek Srdan; Mesa Ruben A; Thomas Deborah; Lasho Terra L; Hogan William J; Litzow Mark R; Allred Jacob B; Jones Dan; Byrne Catriona; Zeldis Jerome B; Ketterling Rhett P; McClure Rebecca F; Giles Francis; Kantarjian Hagop M
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Jabbour Elias; Cortes Jorge; Kantarjian Hagop M; Giralt Sergio; Jones Dan; Jones Roy; Giles Francis; Andersson Borje S; Champlin Richard; de Lima Marcos
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Blood 2006;108(4):1421-3.
2006: Koller Charles; Bekele B Nebiyou; Zhou Xian; Park Charles; Estrov Zeev; O'Brien Susan; Keating Michael; Jilani Iman; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
Blood 2006;108(3):1001-6.
2006: Faderl Stefan; Verstovsek Srdan; Cortes Jorge; Ravandi Farhad; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; O'Brien Susan; Koller Charles; Giles Francis J; Wierda William; Kwari Monica; Kantarjian Hagop M
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Quintás-Cardama Alfonso; Kantarjian Hagop M; Giles Francis; Verstovsek Srdan
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Safdar Amar; Rodriguez Gilhen H; Lichtiger Benjamin; Dickey Burton F; Kontoyiannis Dimitrios P; Freireich Emil J; Shpall Elizabeth J; Raad Issam I; Kantarjian Hagop M; Champlin Richard E
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Cancer 2006;106(12):2664-71.
2006: Ravandi Farhad; Jorgensen Jeffrey L; O'Brien Susan M; Verstovsek Srdan; Koller Charles A; Faderl Stefan; Giles Francis J; Ferrajoli Alessandra; Wierda William G; Odinga Shirley; Huang Xuelin; Thomas Deborah A; Freireich Emil J; Jones Dan; Keating Michael J; Kantarjian Hagop M
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Kantarjian Hagop M; Cortes Jorge
New strategies in chronic myeloid leukemia.
International journal of hematology 2006;83(4):289-93.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Khouri Issa; Giles Francis J; Kantarjian Hagop M; Champlin Richard; Wen Sijin; Do Kim-Anh; Smith Susan C; Lerner Susan; Freireich Emil J; Keating Michael J
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Yang Allen S; Doshi Ketan D; Choi Sang-Woon; Mason Joel B; Mannari Rajan K; Gharybian Vazganush; Luna Rene; Rashid Asif; Shen Lanlan; Estecio Marcos R H; Kantarjian Hagop M; Garcia-Manero Guillermo; Issa Jean-Pierre J
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Cancer research 2006;66(10):5495-503.
2006: Thomas Deborah A; Giles Francis J; Albitar Maher; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; O'Brien Susan M; Garcia-Manero Guillermo; Keating Michael J; Pierce Sherry; Zeldis Jerome; Kantarjian Hagop M
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Cortes Jorge E; Talpaz Moshe; O'Brien Susan; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Rios Mary B; Shan Jenny; Kantarjian Hagop M
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Jabbour Elias J; Estey Elihu; Kantarjian Hagop M
Adult acute myeloid leukemia.
Mayo Clinic proceedings. Mayo Clinic 2006;81(2):247-60.
2006: Tsimberidou Apostolia-Maria; Giles Francis J; Estey Elihu; O'Brien Susan; Keating Michael J; Kantarjian Hagop M
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2005: Yee Karen W L; Jabbour Elias; Kantarjian Hagop M; Giles Francis J
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Annals of hematology 2005;84 Suppl 1():18-24.
2005: Faderl Stefan; Do Kim-Anh; Johnson Marcella M; Keating Michael; O'brien Susan; Jilani Iman; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Aguilar Christine; Dey Amanda; Thomas Deborah A; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Current molecular medicine 2005;5(7):615-23.
2005: Jabbour Elias J; Faderl Stefan; Kantarjian Hagop M
Adult acute lymphoblastic leukemia.
Mayo Clinic proceedings. Mayo Clinic 2005;80(11):1517-27.
2005: Gao H; Lee B-N; Talpaz M; Donato N J; Cortes J E; Kantarjian H M; Reuben J M
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1905-11.
2005: Jelinek Jaroslav; Oki Yasuhiro; Gharibyan Vazganush; Bueso-Ramos Carlos; Prchal Josef T; Verstovsek Srdan; Beran Miloslav; Estey Elihu; Kantarjian Hagop M; Issa Jean-Pierre J
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Blood 2005;106(10):3370-3.
2005: Yee Karen W L; Hagey Anne; Verstovsek Srdan; Cortes Jorge; Garcia-Manero Guillermo; O'Brien Susan M; Faderl Stefan; Thomas Deborah; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Albitar Maher; McKeegan Evelyn; Grimm David R; Mueller Toby; Holley-Shanks Rhonda R; Sahelijo Leonardo; Gordon Gary B; Kantarjian Hagop M; Giles Francis J
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Amin H M; Yang Y; Shen Y; Estey E H; Giles F J; Pierce S A; Kantarjian H M; O'Brien S M; Jilani I; Albitar M
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1567-72.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Faderl Stefan; Kantarjian Hagop M
Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
Nature clinical practice. Oncology 2005;2(7):348-55.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Shan Jianqin; Cortes Jorge
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Kantarjian Hagop M; Issa Jean-Pierre J
Decitabine dosing schedules.
Seminars in hematology 2005;42(3 Suppl 2):S17-22.
2005: Issa Jean-Pierre J; Kantarjian Hagop M
Introduction: emerging role of epigenetic therapy: focus on decitabine.
Seminars in hematology 2005;42(3 Suppl 2):S1-2.
2005: Issa Jean-Pierre J; Gharibyan Vazganush; Cortes Jorge; Jelinek Jaroslav; Morris Gail; Verstovsek Srdan; Talpaz Moshe; Garcia-Manero Guillermo; Kantarjian Hagop M
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3948-56.
2005: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Faderl Stephan; Verstovsek Srdan; Thomas Deborah; Garcia-Manero Guillermo; Wierda William; Ferrajoli Alessandra; Kornblau Stephen; Mattiuzzi Gloria N; Tsimberidou Apostolia M; Albitar Maher; O'Brien Susan M; Estey Elihu
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Faderl Stefan; Gandhi Varsha; Keating Michael J; Jeha Sima; Plunkett William; Kantarjian Hagop M
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Issa Jean-Pierre J; Kantarjian Hagop M; Kirkpatrick Peter
Azacitidine.
Nature reviews. Drug discovery 2005;4(4):275-6.
2005: Tefferi Ayalew; Dewald Gordon W; Litzow Mark L; Cortes Jorge; Mauro Michael J; Talpaz Moshe; Kantarjian Hagop M
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(3):390-402.
2005: Patel Hemantkumar S; Kantarjian Hagop M; Bueso-Ramos Carlos E; Medeiros L Jeffrey; Haidar Mohammad A
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.
Genes, chromosomes & cancer 2005;42(1):87-94.
2004: Jilani Iman; Keating Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Albitar Maher
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
Leukemia research 2004;28(12):1255-62.
2004: Hachem Ray Y; Kontoyiannis Dimitrios P; Boktour Maha R; Afif Claude; Cooksley Catherine; Bodey Gerald P; Chatzinikolaou Ioannis; Perego Cheryl; Kantarjian Hagop M; Raad Issam I
Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Cancer 2004;101(7):1594-600.
2004: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Luthra Rajyalakshmi; Giles Francis; Verstovsek Srdan; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Jones Dan; Talpaz Moshe
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Albitar Maher; Do Kim-Anh; Johnson Marcella M; Giles Francis J; Jilani Iman; O'Brien Susan; Cortes Jorge; Thomas Deborah; Rassenti Laura Z; Kipps Thomas J; Kantarjian Hagop M; Keating Michael
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer 2004;101(5):999-1008.
2004: Tsimberidou Apostolia-Maria; Estey Elihu; Whitman Gary J; Dryden Mark J; Ratnam Suresh; Pierce Sherry; Faderl Stefan; Giles Francis; Kantarjian Hagop M; Garcia-Manero Guillermo
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Faderl Stefan; Kantarjian Hagop M
Novel therapies for myelodysplastic syndromes.
Cancer 2004;101(2):226-41.
2004: Verstovsek Srdan; Giles Francis J; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M; O'Brien Susan M
Accelerated and blastic phases of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):753-74, xii.
2004: Cortes Jorge E; O'Brien Susan M; Giles Francis; Alvarez Ricardo H; Talpaz Moshe; Kantarjian Hagop M
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Tsimberidou Apostolia M; Keating Michael J; Giles Francis J; Wierda William G; Ferrajoli Alessandra; Lerner Susan; Beran Miloslav; Andreeff Michael; Kantarjian Hagop M; O'Brien Susan
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Giles Francis J; Vose Julie M; Do Kim-Anh; Johnson Marcella M; Manshouri Taghi; Bociek Gregory; Bierman Philip J; O'Brien Susan M; Kantarjian Hagop M; Armitage James O; Albitar Maher
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Leukemia research 2004;28(6):595-604.
2004: Sanders Kevin E; Ha Chul S; Cortes-Franco Jorge E; Koller Charles A; Kantarjian Hagop M; Cox James D
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
Cancer 2004;100(10):2176-80.
2004: Hu Qinglong; Dey Amanda L; Yang Ying; Shen Yu; Jilani Iman B; Estey Elihu H; Kantarjian Hagop M; Giles Francis J; Albitar Maher
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M; O'Brien Susan M; Estey Elihu; Beran Miloslav
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Kurzrock Razelle; Albitar Maher; Cortes Jorge E; Estey Elihu H; Faderl Stefan H; Garcia-Manero Guillermo; Thomas Deborah A; Giles Francis J; Ryback Mary Ellen; Thibault Alain; De Porre P; Kantarjian Hagop M
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Scappini Barbara; Gatto Simona; Onida Francesco; Ricci Clara; Divoky Vladimir; Wierda William G; Andreeff Michael; Dong Li; Hayes Kimberly; Verstovsek Srdan; Kantarjian Hagop M; Beran Miloslav
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Cancer 2004;100(7):1459-71.
2004: Giles Francis J; Tallman Martin S; Garcia-Manero Guillermo; Cortes Jorge E; Thomas Deborah A; Wierda William G; Verstovsek Srdan; Hamilton Marta; Barrett Emma; Albitar Maher; Kantarjian Hagop M
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Weiser Mary Ann; Cabanillas Maria E; Konopleva Marina; Thomas Deborah A; Pierce Sherry A; Escalante Carmen P; Kantarjian Hagop M; O'Brien Susan M
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Cancer 2004;100(6):1179-85.
2004: Issa Jean-Pierre J; Garcia-Manero Guillermo; Giles Francis J; Mannari Rajan; Thomas Deborah; Faderl Stefan; Bayar Emel; Lyons John; Rosenfeld Craig S; Cortes Jorge; Kantarjian Hagop M
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Bueso-Ramos Carlos E; Rocha Frederico C; Shishodia Shishir; Medeiros L Jeffrey; Kantarjian Hagop M; Vadhan-Raj Saroj; Estrov Zeev; Smith Terry L; Nguyen Martin H; Aggarwal Bharat B
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
Human pathology 2004;35(2):246-53.
2004: Sneed Thomas B; Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Rios Mary Beth; Bekele B Nebiyou; Zhou Xian; Resta Debra; Wierda William; Faderl Stefan; Giles Francis; Cortes Jorge E
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: O'Brien Susan M; Kantarjian Hagop M; Thomas Deborah A; Cortes Jorge; Giles Francis J; Wierda William G; Koller Charles A; Ferrajoli Alessandra; Browning Mary; Lerner Susan; Albitar Maher; Keating Michael J
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Hennessy Bryan T; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J
DNA methylation in haematological malignancies: the role of decitabine.
Expert opinion on investigational drugs 2003;12(12):1985-93.
2003: Giles Francis J; Vose Julie M; Do Kim-Anh; Johnson Marcella M; Manshouri Taghi; Bociek Gregory; Bierman Philip J; O'Brien Susan M; Keating Michael J; Kantarjian Hagop M; Armitage James O; Albitar Maher
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
British journal of haematology 2003;123(5):850-7.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Kurzrock Razelle; Kantarjian Hagop M; Cortes Jorge E; Singhania Neil; Thomas Deborah A; Wilson Edward F; Wright John J; Freireich Emil J; Talpaz Moshe; Sebti Saïd M
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Blood 2003;102(13):4527-34.
2003: Giles Francis J; Feldman Eric J; Roboz Gail J; Larson Richard A; Mamus Steven W; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; Talpaz Moshe; Beran Miloslav; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Giles Francis J; Fracasso Paula M; Kantarjian Hagop M; Cortes Jorge E; Brown Randy A; Verstovsek Srdan; Alvarado Yesid; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Wright Lisa P; Samson Tom; Cahill Ann; Lambert Paula; Plunkett William; Sznol Mario; DiPersio John F; Gandhi Varsha
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Yang Allen S; Estecio Marcos R H; Garcia-Manero Guillermo; Kantarjian Hagop M; Issa Jean-Pierre J
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
Science (New York, N.Y.) 2003;302(5648):1153; author reply 1153.
2003: Yazji S; Giles F J; Tsimberidou A-M; Estey E H; Kantarjian H M; O'Brien S A; Kurzrock R
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(11):2101-6.
2003: Estey Elihu H; Thall Peter F; Wang Xuemei; Verstovsek Srdan; Cortes Jorge; Kantarjian Hagop M
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Tsimberidou Apostolia M; Giles Francis J; Kantarjian Hagop M; Keating Michael J; O'Brien Susan M
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Leukemia & lymphoma 2003;44(10):1719-25.
2003: Faderl Stefan; Jeha Sima; Kantarjian Hagop M
The biology and therapy of adult acute lymphoblastic leukemia.
Cancer 2003;98(7):1337-54.
2003: Lee Jeong N; Giles Fancis; Huh Yang O; Manshouri Taghi; O'Brien Susan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Beran Miloslav; O'Brien Susan; Thomas Deborah A; Tran Hai T; Cortes-Franco Jorge E; Giles Francis; Estey Elihu; Kantarjian Hagop M
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Tsimberidou Apostolia M; Colburn Dawn E; Welch Mary Alma; Cortes Jorge E; Verstovsek Srdan; O'Brien Susan M; Albitar Maher; Kantarjian Hagop M; Giles Francis J
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Giles Francis J; Shi Gary Guangping; Cortes Jorge E; Thomas Deborah; Keating Anna R; Kantarjian Hagop M; Keating Michael J; O'Brien Susan M
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Gatto Simona; Ball Greg; Onida Francesco; Kantarjian Hagop M; Estey Elihu H; Beran Miloslav
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Blood 2003;102(5):1622-5.
2003: Amin Hesham M; Jilani Iman; Estey Elihu H; Keating Michael J; Dey Amanda L; Manshouri Taghi; Kantarjian Hagop M; Estrov Zeev; Cortes Jorge E; Thomas Deborah A; Giles Francis J; Albitar Maher
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Gatto Simona; Scappini Barbara; Pham Lan; Onida Francesco; Milella Michele; Ball Greg; Ricci Clara; Divoky Vladimir; Verstovsek Srdan; Kantarjian Hagop M; Keating Michael J; Cortes-Franco Jorge E; Beran Miloslav
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Haematologica 2003;88(8):853-63.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Garcia-Manero Guillermo; Faderl Stefan; O'Brien Susan; Cortes Jorge; Talpaz Moshe; Kantarjian Hagop M
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: Estrov Zeev; Shishodia Shishir; Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Aggarwal Bharat B
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
Blood 2003;102(3):987-95.
2003: Giles Francis J; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Cooper Maureen A; Hannah Alison L; Cherrington Julie M; O'Farrell Anne-Marie; Yuen Helene A; Louie Sharianne G; Hong Weiru; Cortes Jorge E; Verstovsek Srdan; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M; Karp Judith E
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Konopleva Marina; Cheng Su-Chun; Cortes Jorge E; Hayes Kimberly J; Pierce Sherry A; Andreeff Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Estey Elihu H
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Torres Harrys A; Bodey Gerald P; Rolston Kenneth V I; Kantarjian Hagop M; Raad Issam I; Kontoyiannis Dimitrios P
Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
Cancer 2003;98(1):86-93.
2003: Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Estrov Zeev
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Blood 2003;102(2):630-7.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: Kurzrock Razelle; Kantarjian Hagop M; Druker Brian J; Talpaz Moshe
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Annals of internal medicine 2003;138(10):819-30.
2003: Giles Francis J; Bekele B Nebiyou; O'Brien Susan; Cortes Jorge E; Verstovsek Srdan; Balerdi Maria; Yared Marwan; Zhou Xian; Kantarjian Hagop M; Keating Michael J; Thall Peter; Albitar Maher
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Thomas Deborah A; Ferrajoli Alessandra; O'Brien Susan; Wathen Jay K; Xiao Lian-Chun; Berry Donald A; Estey Elihu H
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Tsimberidou Apostolia Maria; Waddelow Tracey; Kantarjian Hagop M; Albitar Maher; Giles Francis J
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Leukemia research 2003;27(5):375-80.
2003: Shen LanLan; Toyota Minoru; Kondo Yutaka; Obata Toshiro; Daniel Sophia; Pierce Sherry; Imai Kohzoh; Kantarjian Hagop M; Issa Jean-Pierre J; Garcia-Manero Guillermo
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
Blood 2003;101(10):4131-6.
2003: Cortes Jorge E; Talpaz Moshe; Giles Francis; O'Brien Susan; Rios Mary Beth; Shan Jianqin; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah A; Wierda William; Ferrajoli Allessandra; Jeha Sima; Kantarjian Hagop M
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Giles Francis J; Cooper Maureen A; Silverman Lewis; Karp Judith E; Lancet Jeffrey E; Zangari Maurizio; Shami Paul J; Khan Khuda D; Hannah Alison L; Cherrington Julie M; Thomas Deborah A; Garcia-Manero Guillermo; Albitar Maher; Kantarjian Hagop M; Stopeck Alison T
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: Tsimberidou Apostolia M; Kantarjian Hagop M; Cortes Jorge; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Ferrajoli Alessandra; Wierda William; Alvarado Yesid; O'Brien Susan M; Albitar Maher; Keating Michael J; Giles Francis J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Manshouri Taghi; Do Kim-anh; Wang Xuemei; Giles Francis J; O'Brien Susan M; Saffer Helen; Thomas Deborah; Jilani Iman; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Blood 2003;101(7):2507-13.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Giles Francis J; Faderl Stefan; Thomas Deborah A; Cortes Jorge E; Garcia-Manero Guillermo; Douer Dan; Levine Alexandra M; Koller Charles A; Jeha Sima S; O'Brien Susan M; Estey Elihu H; Kantarjian Hagop M
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Mattiuzzi Gloria N; Cortes Jorge E; Talpaz Moshe; Reuben James; Rios Mary Beth; Shan Jianjin; Kontoyiannis Dimitrios; Giles Francis J; Raad Issam; Verstovsek Srdan; Ferrajoli Alessandra; Kantarjian Hagop M
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Faderl Stefan; Lotan Reuben; Kantarjian Hagop M; Harris David; Van Quin; Estrov Zeev
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Leukemia research 2003;27(3):259-66.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Garcia-Manero Guillermo; Jeha Sima; Daniel Jerry; Williamson Jason; Albitar Maher; Kantarjian Hagop M; Issa Jean-Pierre J
Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia.
Cancer 2003;97(3):695-702.
2003: Kantarjian Hagop M; Talpaz Moshe; Cortes Jorge; O'Brien Susan; Faderl Stefan; Thomas Deborah; Giles Francis; Rios Mary Beth; Shan Jianqin; Arlinghaus Ralph
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Jeha Sima; Rios Mary Beth; Letvak Laurie; Bochinski Kathy; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Thomas Deborah A; Cortes Jorge; Kantarjian Hagop M
New agents in the treatment of acute lymphocytic leukaemia.
Best practice & research. Clinical haematology 2002;15(4):771-90.
2002: Ricci Clara; Scappini Barbara; Divoky Vladimir; Gatto Simona; Onida Francesco; Verstovsek Srdan; Kantarjian Hagop M; Beran Miloslav
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Cancer research 2002;62(21):5995-8.
2002: Aguayo Alvaro; Kantarjian Hagop M; Estey Elihu H; Giles Francis J; Verstovsek Srdan; Manshouri Taghi; Gidel Christy; O'Brien Susan; Keating Michael J; Albitar Maher
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Onida Francesco; Ball Greg; Kantarjian Hagop M; Smith Terry L; Glassman Armand; Albitar Maher; Scappini Barbara; Rios Mary Beth; Keating Michael J; Beran Miloslav
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Cancer 2002;95(8):1673-84.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Giralt Sergio A; Rios Mary Beth; Shan Jianqin; Giles Francis J; Thomas Deborah A; Faderl Stefan; De Lima Marcos; Garcia-Manero Guillermo; Champlin Richard; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Esmaeli Bita; Prieto Victor G; Butler Charles E; Kim Stella K; Ahmadi M Amir; Kantarjian Hagop M; Talpaz Moshe
Severe periorbital edema secondary to STI571 (Gleevec).
Cancer 2002;95(4):881-7.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Albitar Maher; Manshouri Taghi; Shen Yu; Liu Diane; Beran Miloslav; Kantarjian Hagop M; Rogers Anna; Jilani Iman; Lin Chung Wu; Pierce Sherry; Freireich Emil J; Estey Elihu H
Myelodysplastic syndrome is not merely "preleukemia".
Blood 2002;100(3):791-8.
2002: Kantarjian Hagop M; Cortes Jorge E; Rowe Jacob M; Kurzrock Razelle
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Seminars in hematology 2002;39(3 Suppl 2):36-8.
2002: Cortes Jorge E; Kurzrock Razelle; Kantarjian Hagop M
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Seminars in hematology 2002;39(3 Suppl 2):26-30.
2002: Garcia-Manero Guillermo; Daniel Jerry; Smith Terry L; Kornblau Steven M; Lee Ming-Sheng; Kantarjian Hagop M; Issa Jean-Pierre J
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2217-24.
2002: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Smith Terry L; Giles Francis J; Faderl Stefan; Thomas Deborah A; Garcia-Manero Guillermo; Issa Jean-Pierre J; Andreeff Michael; Kornblau Steven M; Koller Charles; Beran Milosav; Keating Michael; Rios Mary Beth; Shan Jenny; Resta Debra; Capdeville Renaud; Hayes Kimberly; Albitar Maher; Freireich Emil J; Cortes Jorge E
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Smith Terry L; Rios Mary Beth; Shan Jianqin; Yang Ying; Giles Francis J; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Jeha Sima; Wierda William; Issa Jean-Pierre J; Kornblau Steven M; Keating Michael; Resta Debra; Capdeville Renaud; Talpaz Moshe
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Giles Francis J; Cortes Jorge E; Thomas Deborah A; Garcia-Manero Guillermo; Faderl Stephan; Jeha Sima; De Jager Robert L; Kantarjian Hagop M
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Ravandi Farhad; Cortes Jorge; Estrov Zeev; Thomas Deborah; Giles Francis J; Huh Yang O; Pierce Sherry; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Alvarado Yesid; Kantarjian Hagop M; Cortes Jorge E; Apostolidou Efrosynl; Bivins Carol; Giles Francis J
Troxacitabine activity in extramedullary myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2002;7(3):179-85.
2002: Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Kantarjian Hagop M
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
Reviews in clinical and experimental hematology 2002;6(2):142-60; discussion 200-2.
2002: Garcia-Manero Guillermo; Bueso-Ramos Carlos; Daniel Jerry; Williamson Jason; Kantarjian Hagop M; Issa Jean-Pierre J
DNA methylation patterns at relapse in adult acute lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1897-903.
2002: Faderl Stefan; Thall Peter F; Kantarjian Hagop M; Estrov Zeev
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
British journal of haematology 2002;117(4):869-74.
2002: Faderl S; Keating M J; Do K-A; Liang S-Y; Kantarjian H M; O'Brien S; Garcia-Manero G; Manshouri T; Albitar M
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(6):1045-52.
2002: Estey Elihu H; Thall Peter F; Giles Francis J; Wang Xue-Mei; Cortes Jorge E; Beran Miloslav; Pierce Sherry A; Thomas Deborah A; Kantarjian Hagop M
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Estey Elihu H; Giles Francis J; Beran Miloslav; O'Brien Susan; Pierce Sherry A; Faderl Stefan H; Cortes Jorge E; Kantarjian Hagop M
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Dabaja Bouthaina S; Ha Chul S; Thomas Deborah A; Wilder Richard B; Gopal Ramesh; Cortes Jorge; Bueso-Ramos Carlos; Hess Mark A; Cox James D; Kantarjian Hagop M
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Cancer 2002;94(10):2738-44.
2002: Scappini Barbara; Onida Francesco; Kantarjian Hagop M; Dong Li; Verstovsek Srdan; Keating Michael J; Beran Miloslav
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Cancer 2002;94(10):2653-62.
2002: Kantarjian Hagop M
Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2415-6.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Tsimberidou Apostolia M; O'Brien Susan M; Cortes Jorge E; Faderl Stefan; Andreeff Michael; Kantarjian Hagop M; Keating Michael J; Giles Francis J
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop M
Current therapy of chronic myelogenous leukemia.
Internal medicine (Tokyo, Japan) 2002;41(4):254-64.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Talpaz Moshe; Silver Richard T; Druker Brian J; Goldman John M; Gambacorti-Passerini Carlo; Guilhot Francois; Schiffer Charles A; Fischer Thomas; Deininger Michael W N; Lennard Anne L; Hochhaus Andreas; Ottmann Oliver G; Gratwohl Alois; Baccarani Michele; Stone Richard; Tura Sante; Mahon Francois-Xavier; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; Kantarjian Hagop M; Sawyers Charles L
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Giles Francis J; Garcia-Manero Guillermo; Cortes Jorge E; Baker Sharyn D; Miller Carol B; O'Brien Susan M; Thomas Deborah A; Andreeff Michael; Bivins Carol; Jolivet Jacques; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):656-64.
2002: Onida Francesco; Kantarjian Hagop M; Smith Terry L; Ball Greg; Keating Michael J; Estey Elihu H; Glassman Armand B; Albitar Maher; Kwari Monica I; Beran Miloslav
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Blood 2002;99(3):840-9.
2002: Weiser Mary A; O'Brien Susan; Thomas Deborah A; Pierce Sherry A; Lam Tony P; Kantarjian Hagop M
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Cancer 2002;94(2):285-91.
2002: Giles Francis J; Keating Armand; Goldstone Anthony H; Avivi Irit; Willman Cheryl L; Kantarjian Hagop M
Acute myeloid leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():73-110.
2001: Scappini B; Onida F; Kantarjian H M; Dong L; Verstovsek S; Keating M J; Beran M
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3884-93.
2001: Estey E H; Thall P F; Cortes J E; Giles F J; O'Brien S; Pierce S A; Wang X; Kantarjian H M; Beran M
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Faderl S; Estrov Z; Kantarjian H M; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski J M; Priebe W
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Anticancer research 2001;21(6A):3777-84.
2001: Kantarjian H M; Shan J; Smith T; Talpaz M; Kozuch P; Rios M B; Cortes J; Giles F J; O'Brien S
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Kantarjian H M; Talpaz M
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Seminars in oncology 2001;28(5 Suppl 17):9-18.
2001: Albitar M; Manshouri T; Gidel C; Croce C; Kornblau S; Pierce S; Kantarjian H M
Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia.
Leukemia research 2001;25(10):859-64.
2001: Kantarjian H M; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien S M
Homoharringtonine: history, current research, and future direction.
Cancer 2001;92(6):1591-605.
2001: Aboul-Nasr R; O'Brien S; Freireich E J; Ginsberg C F; Kantarjian H M; Koller C A; Keating M J; Albitar M
"T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.
Leukemia & lymphoma 2001;42(5):1023-31.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Dabaja B S; O'Brien S M; Kantarjian H M; Cortes J E; Thomas D A; Albitar M; Schlette E S; Faderl S; Sarris A; Keating M J; Giles F J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Giles F J; Kantarjian H M; Kornblau S M; Thomas D A; Garcia-Manero G; Waddelow T A; David C L; Phan A T; Colburn D E; Rashid A; Estey E H
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Ibrahim S; Keating M; Do K A; O'Brien S; Huh Y O; Jilani I; Lerner S; Kantarjian H M; Albitar M
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood 2001;98(1):181-6.
2001: Giles F J; Shen Y; Kantarjian H M; Korbling M J; O'Brien S; Anderlini P; Donato M; Pierce S; Keating M J; Freireich E J; Estey E
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Ravandi F; Hayes K; Cortes J; Albitar M; Glassman A; Talpaz M; Kantarjian H M
Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.
Cancer 2001;91(9):1704-8.
2001: Ferrajoli A; Manshouri T; Estrov Z; Keating M J; O'Brien S; Lerner S; Beran M; Kantarjian H M; Freireich E J; Albitar M
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):795-9.
2001: O'Brien S M; Kantarjian H M; Cortes J; Beran M; Koller C A; Giles F J; Lerner S; Keating M
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: Fleming R V; Kantarjian H M; Husni R; Rolston K; Lim J; Raad I; Pierce S; Cortes J; Estey E
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Leukemia & lymphoma 2001;40(5-6):511-20.
2001: Thomas D A; Kantarjian H M
Lymphoblastic lymphoma.
Hematology/oncology clinics of North America 2001;15(1):51-95, vi.
2001: Kantarjian H M
Adult acute lymphocytic leukemia. Future research directions.
Hematology/oncology clinics of North America 2001;15(1):207-11, viii.
2001: Giles F J; Cortes J E; Baker S D; Thomas D A; O'Brien S; Smith T L; Beran M; Bivins C; Jolivet J; Kantarjian H M
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2001: Faderl S; Gidel C; Kantarjian H M; Manshouri T; Keating M; Albitar M
Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia.
Leukemia research 2001;25(1):39-43.
2000: Garcia-Manero G; Kantarjian H M
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Hematology/oncology clinics of North America 2000;14(6):1381-96, x-xi.
2000: Kantarjian H M
Adult acute lymphocytic leukemia. Introduction and questions related to current programs.
Hematology/oncology clinics of North America 2000;14(6):1205-8, VII.
2000: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of minimal residual disease in leukemia.
International journal of oncology 2000;17(6):1277-87.
2000: Tannir N M; Talpaz M; Ghazal H; Proothi S; Kantarjian H M
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
Leukemia & lymphoma 2000;39(5-6):647-50.
2000: Thomas D A; Kantarjian H M
Current role of thalidomide in cancer treatment.
Current opinion in oncology 2000;12(6):564-73.
2000: Ibrahim S; Estey E H; Pierce S; Glassman A; Keating M; O'Brien S; Kantarjian H M; Albitar M
11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
American journal of clinical pathology 2000;114(5):793-7.
2000: Faderl S; Kantarjian H M; Estey E; Manshouri T; Chan C Y; Rahman Elsaied A; Kornblau S M; Cortes J; Thomas D A; Pierce S; Keating M J; Estrov Z; Albitar M
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Faderl S; Kantarjian H M; Talpaz M; O'Brien S
New treatment approaches for chronic myelogenous leukemia.
Seminars in oncology 2000;27(5):578-86.
2000: Kantarjian H M; Giles F J; O'Brien S; Giralt S; Talpaz M
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Kantarjian H M; Talpaz M; Smith T L; Cortes J; Giles F J; Rios M B; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: Romaguera J E; Khouri I F; Kantarjian H M; Hagemeister F B; Rodriguez M A; McLaughlin P; Sarris A H; Younes A; Rodriguez J; Cabanillas F
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.
Leukemia & lymphoma 2000;39(1-2):77-85.
2000: Reuben J M; Lee B N; Johnson H; Fritsche H; Kantarjian H M; Talpaz M
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1671-7.
2000: Huh Y O; Smith T L; Collins P; Bueso-Ramos C; Albitar M; Kantarjian H M; Pierce S A; Freireich E J
Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry.
Leukemia & lymphoma 2000;37(3-4):319-31.
2000: Giles F J; Wong G C; Clark S J; Pierce S; Kantarjian H M; Keating M J
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):87-95.
2000: Haidar M A; Manshouri T; Keating M J; Kantarjian H M; Freireich E J; Mehta K; Albitar M
Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice.
International journal of oncology 2000;16(3):561-5.
2000: Kantarjian H M; O'Brien S; Smith T L; Cortes J; Giles F J; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha C S; Keating M J; Murphy S; Freireich E J
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: Faderl S; Kantarjian H M; Thomas D A; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
2000: Beran M; Kantarjian H M
Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies.
Annals of the New York Academy of Sciences 2000;922():247-59.
1999: Kantarjian H M; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios M B; Croce C M; Albitar M
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Faderl S; Thall P F; Kantarjian H M; Talpaz M; Harris D; Van Q; Beran M; Kornblau S M; Pierce S; Estrov Z
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4041-7.
1999: Giles F J; O'Brien S M; Santini V; Gandhi V; Plunkett W; Seymour J F; Robertson L E; Kantarjian H M; Keating M J
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Koller C A; Kantarjian H M; Feldman E J; O'Brien S; Rios M B; Estey E; Keating M
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Cancer 1999;86(11):2246-51.
1999: Ravandi F; Cortes J; Albitar M; Arlinghaus R; Qiang Guo J; Talpaz M; Kantarjian H M
Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.
British journal of haematology 1999;107(3):581-6.
1999: Sacchi S; Kantarjian H M; Freireich E J; O'Brien S; Cortes J; Rios M B; Kornblau S; Giles F J; Koller C; Gajewski J; Talpaz M
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Estrov Z; Manna S K; Harris D; Van Q; Estey E H; Kantarjian H M; Talpaz M; Aggarwal B B
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood 1999;94(8):2844-53.
1999: Faderl S; Estrov Z; Kantarjian H M; Thomas D; Cortes J; Manshouri T; Chan C C; Hays K J; Pierce S; Albitar M
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Cytokines, cellular & molecular therapy 1999;5(3):159-63.
1999: Giles F J; Kantarjian H M; Cortes J; Thomas D A; Talpaz M; Manshouri T; Albitar M
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Seong D; Kantarjian H M; Albitar M; Arlinghaus R; Xu J; Talpaz M; Rios M B; Guo J Q; O'Brien S; Siciliano M
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):955-9.
1999: Faderl S; Talpaz M; Estrov Z; Kantarjian H M
Chronic myelogenous leukemia: biology and therapy.
Annals of internal medicine 1999;131(3):207-19.
1999: Faderl S; Kantarjian H M; Manshouri T; Chan C Y; Pierce S; Hays K J; Cortes J; Thomas D; Estrov Z; Albitar M
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1855-61.
1999: Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian H M
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: Ravandi-Kashani F; Cortes J; Talpaz M; Kantarjian H M
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
Cancer 1999;85(12):2583-8.
1999: Aboul-Nasr R; Estey E H; Kantarjian H M; Freireich E J; Andreeff M; Johnson B J; Albitar M
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens.
American journal of clinical pathology 1999;111(6):753-8.
1999: Weinkauff R; Estey E H; Starostik P; Hayes K; Huh Y O; Hirsch-Ginsberg C; Andreeff M; Keating M; Kantarjian H M; Freireich E J; Albitar M
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
American journal of clinical pathology 1999;111(6):733-40.
1999: Dabaja B S; Faderl S; Thomas D; Cortes J; O'Brien S; Nasr F; Pierce S; Hayes K; Glassman A; Keating M; Kantarjian H M
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):869-72.
1999: Faderl S; Talpaz M; Kantarjian H M; Estrov Z
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood 1999;93(9):2755-9.
1999: Cortes J E; Kantarjian H M; O'Brien S; Giles F; Keating M J; Freireich E J; Estey E H
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Faderl S; Kantarjian H M; Talpaz M
Chronic myelogenous leukemia: update on biology and treatment.
Oncology (Williston Park, N.Y.) 1999;13(2):169-80; discussion 181, 184.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Aguayo A; Cortes J E; Kantarjian H M; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating M J
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1998: Beran M; Estey E; O'Brien S M; Giles F J; Koller C A; Kornblau S; Keating M; Kantarjian H M
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia & lymphoma 1998;31(5-6):521-31.
1998: Estrov Z; Thall P F; Talpaz M; Estey E H; Kantarjian H M; Andreeff M; Harris D; Van Q; Walterscheid M; Kornblau S M
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
Blood 1998;92(9):3090-7.
1998: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
Blood 1998;91(11):3995-4019.
1998: Schenk T M; Keyhani A; Bottcher S; Kliche K O; Goodacre A; Guo J Q; Arlinghaus R B; Kantarjian H M; Andreeff M
Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(5):666-74.
1998: Seong D; Thall P; Kantarjian H M; Talpaz M; Swantkowski J; Xu J; Shen Y; Glassman A; Ramagli L; Siciliano M J
Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):861-7.
1998: Sacchi S; Kantarjian H M; Smith T L; O'Brien S; Pierce S; Kornblau S; Beran M; Keating M J; Talpaz M
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):882-9.
1998: Kantarjian H M; Giles F J; O'Brien S M; Talpaz M
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
Hematology/oncology clinics of North America 1998;12(1):31-80.
1997: Kantarjian H M; Talpaz M; O'Brien S; Kurzrock R; Gutterman J; Keating M J; McCredie K B; Freireich E J
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: Koller C A; Kantarjian H M; Thomas D; O'Brien S; Rios M B; Kornblau S; Murphy S; Keating M
The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(12):2039-44.
1997: Kantarjian H M; O'Brien S M; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios M B; de Vos D; Talpaz M
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1617-20.
1997: Sacchi S; Kantarjian H M; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating M J; Talpaz M
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1610-6.
1997: Bseiso A W; Kantarjian H M; Guo J Q; Cortes J; Talpaz M; Koller C; AlBitar M; Keating M; Arlinghaus R
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(9):1583-7.
1997: Rodriguez-Monge E J; Cortes J E; O'Brien S; Talpaz M; Kantarjian H M
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Cancer 1997;80(3):396-400.
1997: Talpaz M; Kantarjian H M; O'Brien S; Kurzrock R
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):291-305.
1997: Cortes J; Kantarjian H M; Giralt S; Talpaz M
Natural history and staging of chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):277-90.
1997: Kantarjian H M; O'Brien S M; Estey E; Giralt S; Beran M; Rios M B; Keating M; de Vos D; Talpaz M
Decitabine studies in chronic and acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 1():S35-6.
1996: Kornblau S M; Gandhi V; Andreeff H M; Beran M; Kantarjian H M; Koller C A; O'Brien S; Plunkett W; Estey E
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1563-9.
1996: Ghaddar H M; Pierce S; Kantarjian H M; Freireich E J; Keating M J; Estey E H
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Leukemia & lymphoma 1996;22(1-2):71-6.
1996: Anderlini P; Ghaddar H M; Smith T L; Pierce S; Kantarjian H M; O'Brien S; Keating M J; Freireich E J; Estey E H
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):964-9.
1996: Khouri I F; Kantarjian H M; Talpaz M; Giralt S; Rios M O; Hester J P; Champlin R E; Deisseroth A B
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.
Bone marrow transplantation 1996;17(5):775-9.
1996: Kantarjian H M; Estey E H; Keating M A
New chemotherapeutic agents in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 1():S4-6.
1996: Anderlini P; Luna M; Kantarjian H M; O'Brien S; Pierce S; Keating M J; Estey E H
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):600-8.
1996: Kantarjian H M; O'Brien S; Anderlini P; Talpaz M
Treatment of myelogenous leukemia: current status and investigational options.
Blood 1996;87(8):3069-81.
1996: Escudier S M; Albitar M; Robertson L E; Andreeff M; Pierce S; Kantarjian H M
Acute lymphoblastic leukemia following preleukemic syndromes in adults.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):473-7.
1996: Kantarjian H M; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang L Y; Rios M B; Keating M J; Meyer M
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):396-401.
1996: van Besien K W; Mehra R C; Giralt S A; Kantarjian H M; Pugh W C; Khouri I F; Moon Y; Williams P; Andersson B S; Przepiorka D; McCarthy P L; Gajewski J L; Deisseroth A B; Cabanillas F F; Champlin R
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
The American journal of medicine 1996;100(3):299-307.
1996: Estrov Z; Talpaz M; Zipf T F; Kantarjian H M; Ku S; Ouspenskaia M V; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Journal of cellular physiology 1996;166(3):618-30.
1996: Escudier S M; Kantarjian H M; Estey E H
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Leukemia & lymphoma 1996;20(5-6):435-9.
1996: Pollicardo N; O'Brien S; Estey E H; al-Bitar M; Pierce S; Keating M; Kantarjian H M
Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(1):27-31.
1996: Smith T L; Lee J J; Kantarjian H M; Legha S S; Raber M N
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):287-95.
1996: Majlis A; Smith T L; Talpaz M; O'Brien S; Rios M B; Kantarjian H M
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):196-203.
1995: Cortes J E; Kantarjian H M
Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy.
Cancer 1995;76(12):2393-417.
1995: Preti H A; Huh Y O; O'Brien S M; Andreeff M; Pierce S T; Keating M; Kantarjian H M
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
Cancer 1995;76(9):1564-70.
1995: Anderlini P; Benjamin R S; Wong F C; Kantarjian H M; Andreeff M; Kornblau S M; O'Brien S; Mackay B; Ewer M S; Pierce S A
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2827-34.
1995: Verschraegen C F; Kantarjian H M; Hirsch-Ginsberg C; Lee M S; O'Brien S; Rios M B; Stass S A; Keating M; Talpaz M
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
Cancer 1995;76(6):992-7.
1995: Chucrallah A E; Stass S A; Huh Y O; Albitar M; Kantarjian H M
Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes.
Cancer 1995;76(6):985-91.
1995: Seong D C; Kantarjian H M; Ro J Y; Talpaz M; Xu J; Robinson J R; Deisseroth A B; Champlin R E; Siciliano M J
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
Blood 1995;86(6):2343-9.
1995: Cortes J; O'Brien S M; Pierce S; Keating M J; Freireich E J; Kantarjian H M
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Blood 1995;86(6):2091-7.
1995: Haidar M A; Cao X B; Manshouri T; Chan L L; Glassman A; Kantarjian H M; Keating M J; Beran M S; Albitar M
p16INK4A and p15INK4B gene deletions in primary leukemias.
Blood 1995;86(1):311-5.
1995: Verschraegen C F; Talpaz M; Hirsch-Ginsberg C F; Pherwani R; Rios M B; Stass S A; Kantarjian H M
Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia.
Blood 1995;85(10):2705-10.
1995: Estey E H; Kantarjian H M; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Cytokines and molecular therapy 1995;1(1):21-8.
1995: Kantarjian H M; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios M B; Smith T L; Calvert L; Deisseroth A B
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):553-9.
1995: Kantarjian H M; Smith T L; O'Brien S; Beran M; Pierce S; Talpaz M
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Annals of internal medicine 1995;122(4):254-61.
1995: Cortes J E; Talpaz M; Beran M; O'Brien S M; Rios M B; Stass S; Kantarjian H M
Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
Cancer 1995;75(2):464-70.
1995: Hester J P; Dignani M C; Anaissie E J; Kantarjian H M; O'Brien S; Freireich E J
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
Journal of clinical apheresis 1995;10(4):188-93.
1994: Kantarjian H M; Talpaz M
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Seminars in oncology 1994;21(6 Suppl 14):8-13.
1994: Gandhi V; Du M; Kantarjian H M; Plunkett W
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(9):1463-8.
1994: Kantarjian H M; O'Brien S; Smith T; Estey E H; Beran M; Preti A; Pierce S; Keating M J
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: Kantarjian H M
Adult acute lymphocytic leukemia: critical review of current knowledge.
The American journal of medicine 1994;97(2):176-84.
1994: Ghaddar H M; Plunkett W; Kantarjian H M; Pierce S; Freireich E J; Keating M J; Estey E H
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(8):1269-74.
1994: Preti H A; O'Brien S; Giralt S; Beran M; Pierce S; Kantarjian H M
Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.
The American journal of medicine 1994;97(1):60-5.
1994: Kantarjian H M; Talpaz M; Andersson B; Khouri I; Giralt S; Rios M B; Champlin R; Hester J; Deisseroth A B
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Bone marrow transplantation 1994;14(1):57-61.
1994: Preti A; Kantarjian H M
Management of adult acute lymphocytic leukemia: present issues and key challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1312-22.
1994: Seymour J F; Pierce S A; Kantarjian H M; Keating M J; Estey E H
Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(5):823-6.
1994: Huh Y O; Pugh W C; Kantarjian H M; Stass S A; Cork A; Trujillo J M; Keating M J
Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.
American journal of clinical pathology 1994;101(3):283-9.
1994: Preti H A; Kantarjian H M
Acute lymphocytic leukemia in adults: an update.
Texas medicine 1994;90(1):52-9.
1994: Preti A; Kantarjian H M; Estey E; Huh Y; Keating M; Pierce S; Hirsch-Ginsberg C; Yee G; Stass S A
Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.
Hematologic pathology 1994;8(4):155-67.
1993: Anaissie E J; Kontoyiannis D P; Vartivarian S; Kantarjian H M; O'Brien S; Giralt S A; Andersson B S; Karl C; Champlin R E; Bodey G P
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(6):1022-31.
1993: Kantarjian H M; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating M J
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Cancer 1993;72(10):2950-5.
1993: Kantarjian H M; Deisseroth A; Kurzrock R; Estrov Z; Talpaz M
Chronic myelogenous leukemia: a concise update.
Blood 1993;82(3):691-703.
1993: Estrov Z; Talpaz M; Kantarjian H M; Zipf T F; McClain K L; Kurzrock R
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Cancer research 1993;53(14):3289-93.
1993: Jaiyesimi I A; Kantarjian H M; Estey E H
Advances in therapy for hairy cell leukemia. A review.
Cancer 1993;72(1):5-16.
1993: Giralt S A; Kantarjian H M; Talpaz M; Rios M B; Del Giglio A; Andersson B S; Przepiorka D; Deisseroth A B; Champlin R E
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1055-61.
1993: Robertson L E; Hall R; Keating M J; Estey E; Kantarjian H M; McLaughlin P; Hagemeister F B; Plunkett W
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Kantarjian H M; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios M B; Plunkett W; Keating M J
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: Estrov Z; Markowitz A B; Kurzrock R; Wetzler M; Kantarjian H M; Ferrajoli A; Gutterman J U; Talpaz M
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(2):214-20.
1993: Zhao L; Kantarjian H M; Van Oort J; Cork A; Trujillo J M; Liang J C
Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(2):168-71.
1993: Kantarjian H M; Estey E H; Keating M J
Treatment of therapy-related leukemia and myelodysplastic syndrome.
Hematology/oncology clinics of North America 1993;7(1):81-107.
1993: Derderian P M; Kantarjian H M; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
The American journal of medicine 1993;94(1):69-74.
1993: Kantarjian H M; Talpaz M
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Leukemia & lymphoma 1993;11 Suppl 1():169-74.
1992: Freireich E J; Cork A; Stass S A; McCredie K B; Keating M J; Estey E H; Kantarjian H M; Trujillo J M
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):500-6.
1992: Kantarjian H M; Keating M J; Estey E H; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Kantarjian H M; Talpaz M; Kontoyiannis D; Gutterman J; Keating M J; Estey E H; O'Brien S; Rios M B; Beran M; Deisseroth A
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):398-405.
1992: Kantarjian H M; Estey E H; O'Brien S; Anaissie E; Beran M; Rios M B; Keating M J; Gutterman J
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Estey E H; Kurzrock R; Kantarjian H M; O'Brien S M; McCredie K B; Beran M; Koller C; Keating M J; Hirsch-Ginsberg C; Huh Y O
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1991: Kantarjian H M; Talpaz M; Dhingra K; Estey E; Keating M J; Ku S; Trujillo J; Huh Y; Stass S; Kurzrock R
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: Kantarjian H M; Talpaz M; Keating M J; Estey E H; O'Brien S; Beran M; McCredie K B; Gutterman J; Freireich E J
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Kantarjian H M; Talpaz M; LeMaistre C F; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth A B
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Cancer 1991;67(12):2959-65.
1991: Estey E H; Kurzrock R; Talpaz M; McCredie K B; O'Brien S; Kantarjian H M; Keating M J; Deisseroth A B; Gutterman J U
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: Kantarjian H M; Schachner J; Keating M J
Fludarabine therapy in hairy cell leukemia.
Cancer 1991;67(5):1291-3.
1991: Kantarjian H M; Childs C; O'Brien S; Huh Y; Beran M; Schachner J; Koller C; Keating M J
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
The American journal of medicine 1991;90(2):223-8.
1990: Haber L M; Childs C C; Hirsch-Ginsberg C; Nellis K; Kantarjian H M; Cork A; Trujillo J M; Stass S A
Strategy for breakpoint cluster region analysis in chronic myelocytic leukemia in a routine clinical laboratory.
American journal of clinical pathology 1990;94(6):762-7.
1990: Walters R; Kantarjian H M; Keating M J; Estey E H; Trujillo J; Cork A; McCredie K B; Freireich E J
The importance of cytogenetic studies in adult acute lymphocytic leukemia.
The American journal of medicine 1990;89(5):579-87.
1990: Kantarjian H M; Redman J R; Keating M J
Fludarabine phosphate therapy in other lymphoid malignancies.
Seminars in oncology 1990;17(5 Suppl 8):66-70.
1990: Kantarjian H M; Hirsch-Ginsberg C; Yee G; Huh Y; Freireich E J; Stass S
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy.
Blood 1990;76(4):808-13.
1990: Dicke K A; Dicke-Evinger M J; Spinolo J A; Estey E H; Kantarjian H M; Spitzer G S
Double intensification including autologous bone marrow transplantation (ABMT) in AML: long term follow-up and detection of residual disease.
Bone marrow transplantation 1990;6 Suppl 1():27-34.
1990: Kantarjian H M; Walters R S; Keating M J; Smith T L; O'Brien S; Estey E H; Huh Y O; Spinolo J; Dicke K; Barlogie B
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Estey E H; Dixon D; Kantarjian H M; Keating M J; McCredie K; Bodey G P; Kurzrock R; Talpaz M; Freireich E J; Deisseroth A B
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Kantarjian H M; Alexanian R; Koller C A; Kurzrock R; Keating M J
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: Kantarjian H M; Kurzrock R; Talpaz M
Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Hematology/oncology clinics of North America 1990;4(2):389-404.
1990: Kurzrock R; Kantarjian H M; Shtalrid M; Gutterman J U; Talpaz M
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Blood 1990;75(2):445-52.
1990: Kantarjian H M; Keating M J; Smith T L; Talpaz M; McCredie K B
Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.
The American journal of medicine 1990;88(1):1-8.
1990: Kantarjian H M; Walters R L; Keating M J; Estey E H; O'Brien S; Schachner J; McCredie K B; Freireich E J
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1990: Estey E H; Kantarjian H M; Beran M; McCredie K B; Keating M J; Deisseroth A; Gutterman J U
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Haematology and blood transfusion 1990;33():732-6.
1989: O'Brien S; Kantarjian H M; Keating M; Gagnon G; Cork A; Trujillo J; McCredie K B
Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1081-6.
1989: Kantarjian H M; Walters R S; Keating M J; Barlogie B; McCredie K B; Freireich E J
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia.
Cancer 1989;64(1):16-22.
1989: Lee M S; LeMaistre A; Kantarjian H M; Talpaz M; Freireich E J; Trujillo J M; Stass S A
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
Blood 1989;73(8):2165-70.
1989: Taylor K M; Shetta M; Talpaz M; Kantarjian H M; Hardikar S; Chinault A C; McCredie K B; Spitzer G
Myeloproliferative disorders: usefulness of X-linked probes in diagnosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(6):419-22.
1989: Kantarjian H M; Keating M J; Walters R S; Koller C A; McCredie K B; Freireich E J
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
Cancer 1989;63(5):813-7.
1989: LeMaistre A; Lee M S; Talpaz M; Kantarjian H M; Freireich E J; Deisseroth A B; Trujillo J M; Stass S A
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia.
Blood 1989;73(4):889-91.
1989: Horwitz L J; Kantarjian H M; Jagannath S; Keating M J; McCredie K B; Spitzer G; Vellekoop L; Zander A R; Dicke K A
Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.
Bone marrow transplantation 1989;4(1):101-5.
1988: Kantarjian H M; Shtalrid M; Kurzrock R; Blick M; Dalton W T; LeMaistre A; Stass S A; McCredie K B; Gutterman J; Freireich E J
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
The American journal of medicine 1988;85(5):639-44.
1988: Kantarjian H M; Walters R S; Smith T L; Keating M J; Barlogie B; McCredie K B; Freireich E J
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia.
Blood 1988;72(5):1784-9.
1988: Lee M S; Chang K S; Freireich E J; Kantarjian H M; Talpaz M; Trujillo J M; Stass S A
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.
Blood 1988;72(3):893-7.
1988: Kantarjian H M; Dixon D; Keating M J; Talpaz M; Walters R S; McCredie K B; Freireich E J
Characteristics of accelerated disease in chronic myelogenous leukemia.
Cancer 1988;61(7):1441-6.
1988: Kantarjian H M; Keating M J; Walters R S; McCredie K B; Freireich E J
The characteristics and outcome of patients with late relapse acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(2):232-8.
1988: Kantarjian H M; Talpaz M; Gutterman J U
Chronic myelogenous leukemia--past, present, and future.
Hematologic pathology 1988;2(2):91-120.
1987: Kantarjian H M; Keating M J
Therapy-related leukemia and myelodysplastic syndrome.
Seminars in oncology 1987;14(4):435-43.
1987: Kantarjian H M; Keating M J; McCredie K B; Walters R; Talpaz M; Smith T L; Freireich E J
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.
Southern medical journal 1987;80(10):1228-32.
1987: Walters R S; Kantarjian H M; Keating M J; Talpaz M; Childs C C; McCredie K B; Freireich E J
Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron.
Cancer 1987;60(8):1708-12.
1987: Kantarjian H M; Keating M J; Talpaz M; Walters R S; Smith T L; Cork A; McCredie K B; Freireich E J
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
The American journal of medicine 1987;83(3):445-54.
1987: Kantarjian H M; Talpaz M; Gutterman J
Biologic therapy of chronic myelogenous leukemia.
Oncology (Williston Park, N.Y.) 1987;1(7):35-40, 48-9, 52.
1987: Talpaz M; Kantarjian H M; McCredie K B; Keating M J; Trujillo J; Gutterman J
Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
Blood 1987;69(5):1280-8.
1987: O'Brien S; Kantarjian H M; Talpaz M; Cork A; Trujillo J; Beran M
The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations.
Hematologic pathology 1987;1(3):167-72.
1987: Keating M J; Estey E; Kantarjian H M; Walters R; Smith T; McCredie K B; Freireich E J
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():120-6.
1987: Kantarjian H M; Talpaz M; Kurzrock R; Keating M J; McCredie K B; Gutterman J; Freireich E J
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():70-4.
1986: Kantarjian H M; Keating M J; Walters R S; Estey E H; McCredie K B; Smith T L; Dalton W T; Cork A; Trujillo J M; Freireich E J
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
The American journal of medicine 1986;80(5):789-97.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Hagop Kantarjian

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Hagop Kantarjian (preview)

All Publications